InVivo Therapeutics (OTC:NVIV) is seeking FDA approval for a humanitarian use device designation for its biopolymer scaffolding product in treatment of traumatic spinal cord injuries.
The Cambridge, Mass.-based firm expects to begin a clinical trial of the scaffolding in acute spinal cord injuries early next year.